DABIGATRAN TEVA 75 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

DABIGATRAN ETEXILATE AS MESYLATE

Disponible depuis:

TEVA ISRAEL LTD

Code ATC:

B01AE07

forme pharmaceutique:

CAPSULES

Composition:

DABIGATRAN ETEXILATE AS MESYLATE 75 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Domaine thérapeutique:

DABIGATRAN ETEXILATE

indications thérapeutiques:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery

Date de l'autorisation:

2020-11-01

Notice patient

PATIENT LEAFLET IN ACCORDANCE
WITH THE PHARMACISTS’
REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s
prescription only
DABIGATRAN TEVA 75 MG
CAPSULES
THE ACTIVE INGREDIENT:
Each capsule of DABIGATRAN TEVA 75 MG
contains:
75 mg dabigatran etexilate (as mesylate)
For information about inactive ingredients see
section 6 – “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE
USING THE MEDICINE.
This leaflet contains concise information about
the medicine. If you have additional questions,
refer to the doctor or the pharmacist.
This medicine has been prescribed for
treatment of your illness. Do not pass it on to
others. It may harm them even if it seems to
you that their illness is similar.
Patient information card:
This card contains important safety
information, which you need to know
before starting treatment with Dabigatran
Teva and during the treatment with
Dabigatran Teva.
The card contains information intended
for both the patient and the healthcare
staff. It provides guidance for patients
on how to minimize the risk of bleeding,
which results from treatment with any of
the anticoagulant preparations.
In addition, the card contains personal
details of the patient and information
regarding the medicine Dabigatran Teva
for the healthcare staff. Present this card
to any healthcare professional involved
in your treatment.
1. WHAT IS THE MEDICINE INTENDED
FOR?
Dabigatran Teva contains the active ingredient
dabigatran etexilate, which belongs to a group
of medicines called “anticoagulants”.
Dabigatran Teva is intended for primary
prevention of thrombosis of the veins following
elective orthopedic surgeries of total knee
replacement or total hip replacement in adults.
THERAPEUTIC CLASS: anticoagulants.
2. BEFORE USING THE MEDICINE
DO NOT USE THIS MEDICINE IF:
·
You are sensitive (allergic) to the
active ingredient or any of the other
ingredients of the medicine (for a list
of inactive ingredients, see section 6).
·
You suffer from a severe impairment
in kidney